Finoriq

Finoriq research workspace

Anika Therapeutics, Inc. (ANIK) Company Overview

Anika Therapeutics, Inc. offers osteoarthritis (OA) pain management products and services, such as. Review ANIK filings, fundamentals, valuation, and ownership on Finoriq.

Company Snapshot

Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Company
Anika Therapeutics, Inc. (ANIK)
Ticker
ANIK
Market Cap
$200.6M
Latest Price
$15.08
Industry
Medical Devices

Open insider transactions

Anika Therapeutics, Inc. (ANIK) Current Valuation Metrics

Static valuation preview for Anika Therapeutics, Inc. (ANIK). Market data retrieved 2026-07-09. Filing currency USD.

MetricValueSource
P/SMarket cap divided by latest TTM revenue.1.84xRevenue | TTM Q1 2026
P/Operating Cash FlowMarket cap divided by latest TTM operating cash flow.33.0xOperating Cash Flow | TTM Q1 2026
Earnings YieldLatest TTM net income divided by market cap.-5.2%Net Income | TTM Q1 2026
Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap.3.0%Operating Cash Flow | TTM Q1 2026
Price / BookMarket cap divided by stockholders' equity.1.59xStockholders' Equity | Q1 2026

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.